Sorafenib Plus Capecitabine Efficacy Assessment in Patients With Advanced Pre-treated Colorectal Cancer
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
Prospective non-randomized phase II study assessing the activity of the
Capecitabine-Sorafenib combination by estimating overall survival of the study population at
a fixed time point (6 months) and, as an exploratory analysis the overall survival of
metabolic responders versus non-responders.
Phase:
Phase 2
Details
Lead Sponsor:
Jules Bordet Institute
Collaborators:
Centre Hospitalier Chretien Cliniques universitaires Saint-Luc- Université Catholique de Louvain Erasme University Hospital Hospital Ambroise Paré Paris INDC Entité Jolimontoise Universiteit Antwerpen